Skip to main content
Clinical Trials/NCT01828437
NCT01828437
Completed
Phase 3

Addition of Pyridoxine to Prednisolone in the Treatment of Infantile Spasms: A Randomized Controlled Trial

Lady Hardinge Medical College1 site in 1 country62 target enrollmentNovember 2012

Overview

Phase
Phase 3
Intervention
Pyridoxine plus prednisolone
Conditions
Infantile Spasms
Sponsor
Lady Hardinge Medical College
Enrollment
62
Locations
1
Primary Endpoint
Proportion of children who achieved complete cessation spasm for at least 48 hours as per parental reports at the end of 2 weeks in both the groups.
Status
Completed
Last Updated
7 years ago

Overview

Brief Summary

Infantile spasms constitute a unique age specific epilepsy syndrome of infancy, characterized by epileptic spasms often accompanied by neurodevelopmental regression and an EEG finding of hypsarrhythmia. When all 3 components are present, the eponym "West syndrome" is commonly used. West syndrome is a catastrophic epileptic encephalopathy. It does not respond well to standard anti-epileptic drugs. Hormonal therapy is the mainstay in the treatment of infantile spasms. This includes adreno-cortico trophic hormone (ACTH) and oral steroids. Variable dose of prednisolone used in the treatment. Oral prednisolone used in usual dose (2mg/kg) has been shown to be less effective as compared to ACTH. High dose prednisolone (4mg/kg) has been used in the treatment of infantile spasms, which has been shown to be as effective as ACTH. Pyridoxine has been used as first line treatment in Japan, however there is paucity of data on the efficacy of combination of pyridoxine with hormonal therapy. There are no studies comparing add on pyridoxine with high prednisolone versus high dose prednisolone alone in the treatment of infantile spasms. Therefore the study has been planned to see whether the addition of pyridoxine with high dose prednisolone in the treatment of infantile spasms improves the efficacy in terms of spasm cessation.

Registry
clinicaltrials.gov
Start Date
November 2012
End Date
March 2014
Last Updated
7 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Satinder Aneja

Director Professor and Head

Lady Hardinge Medical College

Eligibility Criteria

Inclusion Criteria

  • Age in 3months-3years.
  • Presence of epileptic spasms (1 or more clusters per day) with EEG evidence of hypsarrythmia or its variants.

Exclusion Criteria

  • Children with active systemic illness
  • Children with evidence of active tuberculosis
  • Severe Acute Malnutrition (standard deviation scores below median weight for height)
  • Children with recurrent illness/chronic systemic illness
  • Prior treatment of pyridoxine, steroid, or ACTH.

Arms & Interventions

Pyridoxine plus prednisolone

allocated patients receive pyridoxine (30 mg/kg/day) in addition to prednisolone

Intervention: Pyridoxine plus prednisolone

Prednisolone

allocated patients receive prednisolone alone

Intervention: Prednisolone

Outcomes

Primary Outcomes

Proportion of children who achieved complete cessation spasm for at least 48 hours as per parental reports at the end of 2 weeks in both the groups.

Time Frame: 2 weeks

Proportion of children who achieved complete cessation spasm for at least 48 hours as per parental reports at the end of 2 weeks in both the groups.

Secondary Outcomes

  • • Proportion of children who achieved more than 50 % reduction of clinical spasms as per parental reports at the end of 2 weeks(2 weeks)

Study Sites (1)

Loading locations...

Similar Trials